文献速递白血病MDS 与骨髓增殖性肿瘤

在老年急性髓系白血病和高危骨髓增生异常综合征患者的标准强化治疗中加入核输出抑制剂塞利尼索

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
PubMed 文献 · Leukemia · 2022-07-22

本研究为开放标签随机II期试验,纳入102例65岁以上急性髓系白血病患者,随机分配至标准化疗联合或不联合口服塞利尼索。结果显示对照组完全缓解/完全缓解伴不完全恢复率显著高于试验组(80% vs 59%,p=0.018),18个月无事件生存率和总生存率也均以对照组更优;作者结论为加用塞利尼索对老年AML患者的治疗转归产生负面影响。

要点

  • 标准化疗联合塞利尼索组CR/CRi率显著低于对照组(59% vs 80%,p=0.018)。
  • 18个月无事件生存率对照组45% vs 试验组26%(Cox-p=0.012),总生存率58% vs 33%(p=0.009)。
  • 试验组AML和感染并发症导致的死亡率增加。

核心结论

  • 在标准强化化疗基础上加用塞利尼索对老年AML患者的治疗转归产生负面影响。

研究设计与样本

  • 开放标签随机II期研究,纳入102例年龄>65岁(中位69岁,范围65-80岁)的AML患者,随机分配至标准化疗(3+7)联合或不联合口服塞利尼索60 mg每周两次(第1-24天),两组各51例;第二周期给予阿糖胞苷1000 mg/m2每日两次(第1-6天)联合或不联合塞利尼索。

主要发现

  • 对照组CR/CRi率为80%(95%CI 69-91%),试验组为59%(95%CI 45-72%),差异显著(p=0.018)。
  • 18个月时无事件生存率对照组为45%,试验组为26%(Cox-p=0.012);总生存率对照组为58%,试验组为33%(p=0.009)。
  • 试验组AML和感染并发症导致的死亡率增加。
  • 无论接受何种治疗,两周期后MRD状态似乎与生存相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1 inhibitor selinexor to intensive chemotherapy would improve outcome in this population. 102 AML patients > 65 years of age (median 69 (65-80)) were randomly assigned to standard chemotherapy (3 + 7) with or without oral selinexor 60 mg twice weekly (both arms n = 51), days 1-24. In the second cycle, cytarabine 1000 mg/m2 twice daily, days 1-6 with or without selinexor was given. CR/CRi rates were significantly higher in the control arm than in the investigational arm (80% (95% C.I. 69-91%) vs. 59% (45-72%; p = 0.018), respectively). At 18 months, event-free survival was 45% for the control arm versus 26% for the investigational arm (Cox-p = 0.012) and overall survival 58% vs. 33%, respectively (p = 0.009). AML and infectious complications accounted for an increased death rate in the investigational arm. Irrespective of treatment, MRD status after two cycles appeared to be correlated with survival. We conclude that the addition of selinexor to standard chemotherapy does negatively affect the therapeutic outcome of elderly AML patients. (Netherlands Trial Registry number NL5748 (NTR5902), www.trialregister.nl ).

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Janssen JJWM, Löwenberg B, Manz M, et al. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Leukemia. 2022. PMID: 35869267. doi:10.1038/s41375-022-01657-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。